BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
60.18
-2.00 (-3.22%)
At close: Apr 28, 2026
36.87%
Market Cap 25.43B
Revenue (ttm) 1.22B
Net Income (ttm) 54.51M
Shares Out 422.54M
EPS (ttm) 0.13
PE Ratio 466.46
Forward PE n/a
Dividend 0.02 (0.03%)
Ex-Dividend Date Jun 23, 2025
Volume 13,913,520
Average Volume 15,760,426
Open 60.50
Previous Close 62.18
Day's Range 58.96 - 62.19
52-Week Range 38.89 - 122.59
Beta 0.11
RSI 62.49
Earnings Date Apr 30, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,196
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 54.51 million, a decrease of -71.18%.

Financial Statements

News

There is no news available yet.